HANNAH ALISON L.
SEC insider (Form 3/4/5 filer). CIK 0001645600. EVP, Chief Medical Officer at RIGEL PHARMACEUTICALS INC (RIGL) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Jul 8, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies HANNAH ALISON L. has filed insider reports for
- RIGEL PHARMACEUTICALS INC (RIGL): Officer, EVP, Chief Medical Officer
- NEOGENOMICS INC (NEO): Director
HANNAH ALISON L.
CIK: 0001645600
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)2 (33.3%)
Derivative conversions
Awards (A)4 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 8, 2026RIGL
RIGEL PHARMACEUTICALS INC
AwardDirect24.4K shares- - May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
AwardDirect5.8K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
ExerciseDirect12.3K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
AwardDirect12.3K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
ExerciseDirectRestricted Stock Unit
12.3K shares- - May 23, 2025RIGL
RIGEL PHARMACEUTICALS INC
AwardDirect2.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 8, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Award | 24,400 | - | $0 | Direct |
| May 15, 2026 | RIGL RIGEL PHARMACEUTICALS INC | Award | 5,750 | - | $0 | Direct |
| Jun 1, 2025 |  NEO NEOGENOMICS INC | Exercise | 12,254 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Award | 12,254 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Exercise Restricted Stock Unit | 12,254 | - | - | Direct |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | Award | 2,500 | - | - | Direct |
1-6 of 6 transactions